Literature DB >> 16631222

Functional impact of HIV coreceptor-binding site mutations.

Mark J Biscone1, John L Miamidian, John M Muchiri, Sarah S W Baik, Fang-Hua Lee, Robert W Doms, Jacqueline D Reeves.   

Abstract

The bridging sheet region of the gp120 subunit of the HIV-1 Env protein interacts with the major virus coreceptors, CCR5 and CXCR4. We examined the impact of mutations in and adjacent to the bridging sheet region of an X4 tropic HIV-1 on membrane fusion and entry inhibitor susceptibility. When the V3-loop of this Env was changed so that CCR5 was used, the effects of these same mutations on CCR5 use were assayed as well. We found that coreceptor-binding site mutations had greater effects on CXCR4-mediated fusion and infection than when CCR5 was used as a coreceptor, perhaps related to differences in coreceptor affinity. The mutations also reduced use of the alternative coreceptors CCR3 and CCR8 to varying degrees, indicating that the bridging sheet region is important for the efficient utilization of both major and minor HIV coreceptors. As seen before with a primary R5 virus strain, bridging sheet mutations increased susceptibility to the CCR5 inhibitor TAK-779, which correlated with CCR5 binding efficiency. Bridging sheet mutations also conferred increased susceptibility to the CXCR4 ligand AMD-3100 in the context of the X4 tropic Env. However, these mutations had little effect on the rate of membrane fusion and little effect on susceptibility to enfuvirtide, a membrane fusion inhibitor whose activity is dependent in part on the rate of Env-mediated membrane fusion. Thus, mutations that reduce coreceptor binding and enhance susceptibility to coreceptor inhibitors can affect fusion and enfuvirtide susceptibility in an Env context-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631222     DOI: 10.1016/j.virol.2006.03.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

Review 1.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

2.  Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin.

Authors:  Lusine H Demirkhanyan; Mariana Marin; Sergi Padilla-Parra; Changyou Zhan; Kosuke Miyauchi; Maikha Jean-Baptiste; Gennadiy Novitskiy; Wuyuan Lu; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

3.  Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1.

Authors:  Narayanaiah Cheedarla; Jagadish Chandrabose Sundaramurthi; Babu Hemalatha; Brahmaiah Anangi; Manohar Nesakumar; Manickam Ashokkumar; K K Vidya Vijayan; Srikanth Prasad Tripathy; Soumya Swaminathan; S Kalyanaraman Vaniambadi; D Vadakkupattu Ramanathan; Luke Elizabeth Hanna
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-20       Impact factor: 2.205

4.  Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors.

Authors:  Charline Giroud; Yuhong Du; Mariana Marin; Qui Min; Nathan T Jui; Haian Fu; Gregory B Melikyan
Journal:  Assay Drug Dev Technol       Date:  2017 Feb/Mar       Impact factor: 1.738

5.  Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.

Authors:  Caroline Agrawal-Gamse; Fang-Hua Lee; Beth Haggarty; Andrea P O Jordan; Yanjie Yi; Benhur Lee; Ronald G Collman; James A Hoxie; Robert W Doms; Meg M Laakso
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

6.  Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.

Authors:  Qiuxiang Tan; Ya Zhu; Jian Li; Zhuxi Chen; Gye Won Han; Irina Kufareva; Tingting Li; Limin Ma; Gustavo Fenalti; Jing Li; Wenru Zhang; Xin Xie; Huaiyu Yang; Hualiang Jiang; Vadim Cherezov; Hong Liu; Raymond C Stevens; Qiang Zhao; Beili Wu
Journal:  Science       Date:  2013-09-12       Impact factor: 47.728

7.  Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.

Authors:  Michael A Lobritz; Andre J Marozsan; Ryan M Troyer; Eric J Arts
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

8.  Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism.

Authors:  Hanna B Scinto; Sandeep Gupta; Swati Thorat; Muhammad M Mukhtar; Anthony Griffiths; Jennifer Delgado; Elizabeth Plake; Hemant K Vyas; Amanda Strickland; Siddappa N Byrareddy; David C Montefiori; Celia LaBranche; Ranajit Pal; Jim Treece; Sharon Orndorff; Maria Grazia Ferrari; Deborah Weiss; Agnes-Laurence Chenine; Robert McLinden; Nelson Michael; Jerome H Kim; Merlin L Robb; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Ruth M Ruprecht
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

9.  Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet.

Authors:  Marco Schiavone; Giuseppe Fiume; Antonella Caivano; Annamaria De Laurentiis; Cristina Falcone; Francesca Fasanella Masci; Enrico Iaccino; Selena Mimmi; Camillo Palmieri; Antonio Pisano; Marilena Pontoriero; Annalisa Rossi; Annarita Scialdone; Eleonora Vecchio; Concetta Andreozzi; Maria Trovato; Jan Rafay; Boris Ferko; David Montefiori; Angela Lombardi; Giulia Morsica; Guido Poli; Ileana Quinto; Vincenzo Pavone; Piergiuseppe De Berardinis; Giuseppe Scala
Journal:  Int J Mol Sci       Date:  2012-05-10       Impact factor: 6.208

10.  HIV-1 Entry, Inhibitors, and Resistance.

Authors:  Michael A Lobritz; Annette N Ratcliff; Eric J Arts
Journal:  Viruses       Date:  2010-04-29       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.